## CONTENTS

List of Abbreviations (i)
List of Figures (ii)
List of Tables (v)

1.0 Introduction

1.1 Immunohistochemistry 1
1.2 Immunochemical techniques 2
   1.2.1 Enzyme amplification systems 5
   1.2.2 Immunogold techniques 7
   1.2.3 Immunofluorescence 8
   1.2.4 Immunoblotting/dot immunobinding 11
   1.2.4.1 Immobilizing matrices in solid phase immunoassays 12
   1.2.4.2 Applications of immunoblotting and dot immunobinding 14

1.3 Human serum albumin 17
   1.3.1 Functions of albumin 18
1.4 Immunoaffinity based immobilization 19
1.5 Immunoglobulins 21
   1.5.1 Immunoglobulin G 22
1.6 Porcine pepsin 22
1.7 Procedures for producing F(ab)'2 24
1.8 Use of IMAC for purification of immunoglobulins 29
1.9 Objective of the work 32

2.0 Materials 33

3.0 Methods

3.1 Immunological Procedures 35
   3.1.1 Preparation of the antigen 35
   3.1.2 Immunization of rabbits 35
   3.1.3 Immunodiffusion 35
   3.1.4 Isolation and purification of immunoglobulin G from the antiserum 36
   3.1.5 Ion exchange chromatography 36
   3.1.6 Preparation of F(ab) monomer 37
   3.1.7 Formation of F(ab)' 37
   3.1.8 Purification of specific IgG 37
3.1.9 ELISA
3.1.10 Immunoaffinity layering in ELISA
3.1.11 Dot blot/western blot

3.2 Colorimetric Analysis
3.2.1 Determination of protein concentration
3.2.2 Carbohydrate estimation
3.2.3 Aminogroup estimation
3.2.4 Assay of Pepsin

3.3 Chemical modification of Pepsin

3.4 Immobilized Metal ion Affinity Chromatography (IMAC)

3.5 Slab gel electrophoresis
3.5.1 Polyacrylamide gel electrophoresis (PAGE)
3.5.2 SDS polyacrylamide gel electrophoresis (SDS PAGE)
3.5.3 Staining procedures

3.6 Spectral Analysis
3.6.1 UV absorption spectroscopy
3.6.2 Fluorescence spectroscopy
3.6.3 Circular dichroism spectroscopy

3.7 Size exclusion high performance liquid chromatography (HPLC)

4.0 Results

4.1 Immunogenicity of HSA and cross reactivity of anti-HSA antibodies.

4.2 Immunoaffinity layering
4.2.1 Immunodot analysis of HSA by immunoaffinity layering
4.2.2 Effect of time of incubation
4.2.3 Immunodot analysis of HSA with intact anti-HSA-IgG and F(\text{ab})'_2 derived there of.
4.2.4 Immunoaffinity layering using glutaraldehyde crosslinked anti-HSA-IgG
4.2.5 Immunodot analysis of HSA using affinity purified anti-HSA specific antibody.
4.2.6 Immunodot analysis of HSA of human serum using the multiple incubation assay
4.2.7 Studies of albumin aggregation using multiple incubation assay
4.2.8 Multiple incubation assay in ELISA 63
4.2.9 Multiple incubation assay in ELISA using F(ab)', 63

5.0 Modification of Pepsin

5.1 Preparation of Pepsin modified with histidine 66
5.2 Properties of modified pepsin 67
5.2.1 Kinetic behaviour
5.2.1.1 Effect of substrate concentration 67
5.2.1.2 Effect of temperature 67
5.2.1.3 Effect of pH 67
5.2.2 Electrophoretic behaviour 67
5.2.3 Autolysis of pepsin and modified pepsin 71
5.2.4 Spectral studies
5.2.4.1 UV spectroscopy 71
5.2.4.2 Fluorescence spectroscopy 71
5.2.4.3 Circular dichroism of native and modified pepsin 74
5.2.5 Binding of native and modified pepsin on Cu²⁺-IDA Sepharose 74
5.2.6 Elution of Pepsin and modified pepsin bound to Cu²⁺-IDA with EDTA. 74

5.3 Purification and pepsinization of IgG for F(ab)² formation.
5.3.1 Purification of IgG from anti-HSA antiserum. 79
5.3.2 Molecular weight of IgG 79
5.3.3 Cleavage of IgG with modified pepsin and purification of F(ab)', by IMAC 82
5.3.3.1 pH dependent cleavage of IgG 82
5.3.3.2 Temperature dependent cleavage of IgG 85
5.3.3.3 Time dependent cleavage of IgG 85

5.4 Binding of F(ab) monomer to Cu²⁺-IDA Sepharose 85
5.5 Isolation of F(ab)', from unfractionated serum 85
5.6 Size exclusion high performance liquid chromatography (HPLC) 89
5.7 Isolation of F(ab)', dimer in a single tube 89
5.7.1 Isolation of F(ab)', in a single tube from various mammalian species. 93

5.8 Antigenicity of F(ab)', isolated from IgG 93

6.0 Discussion 97
7.0 Summary 113
8.0 Bibliography 116